Dr. Vincenzo Cerundolo is the director of the MRC Human Immunology Unit and head of the Department of Investigative Medicine at the University of Oxford.
Dr. Cerundolo has made significant contributions to our understanding of how our immune cells detect tumor and viral antigens via the major histocompatibility complexes (MHCs), how our T cells recognize lipids through the CD1 receptor, and how anti-cancer T cells congregate in lymph nodes that have been infiltrated by tumor cells. He continues to focus on understanding how the different cells of our immune system interact with each other to coordinate and carry out anti-tumor immune responses, and is using clinical trials to optimize an immunotherapy vaccine approach for patients.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. Cerundolo serves on the CLIP Grant Review Committee and is a member of CRI’s global clinical investigator network.
Cancer, autoimmunity, and chronic inflammation are three aspects of the same problem. The lessons that we can learn from cancer immunology are therefore applicable to many different diseases.
Let's spread the word about Immunotherapy! Click to share this page with your community.